Skip to main contentAll experts

DrBrian Christopher

Adjunct Clinical Associate Professor

School of Medicine

Orcid identifier0000-0002-9871-3732 (opens in a new tab)⁠
  • Adjunct Clinical Associate Professor
    School of Medicine
  • University College Dublin, School of Medicine

RESEARCH INTERESTS

 

I am actively involved in clinical and academic researches. My current / recent works, researches, scholarship and Innovation works are as outlined below:-

 

  • Current active research 2025/2026 - ABX464-107: A randomized, double-blind, multicenter, phase III study to evaluate the long term efficacy              and safety of ABX464 25 mg or 50 mg once daily as a maintenance therapy in subjects with moderately to severely active ulcerative colitis –          Sponsored by Abivax, co-Principal Investigator

 

  • Current active research 2025/ 2026 - M24-885 (Target-CD): A Phase 2a Multicenter, Randomized, Platform Study of Targeted Therapies for the         Treatment of Adult Subjects with Moderate to Severe Crohn's Disease – sponsored by AbbVie, co-Principal Investigator

 

  • Current active research 2025 / 2026 - M25-540 (Revamp): A Phase 3b, Multicenter, Randomized, Open-Label Study of Risankizumab Compared       to Vedolizumab for the Treatment of Adult Subjects With Moderate to Severe Ulcerative Colitis Who are Naïve to Targeted Therapies –                       sponsored by AbbVie, co- Principal Investigator

 

  •  A Phase 3b/4, Multicenter, Parallel-Group, Double-Blind, Placebo-Controlled, Two-Arm, Long-Term Study to Evaluate the Safety and Efficacy of          Saroglitazar Magnesium on Clinical Outcomes in Participants with Primary Biliary Cholangitis (PBC) – sponsored by Zydus Therapeutics Inc.              Submission application for Principal Investigator 2026

 

  • A Phase 2a Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderate to Severe Crohn's       Disease – Current co-principal investigator, study started in January 2025 (Abbvie)

 

  • Co-principal investigator for ABTECT program 2023 – Interventional clinical trial on Inflammatory Bowel Disease (IBD) patients – consists of 2              induction studies: 612 patients each and a single maintenance study around 1100 patients. Treatment arm treated with ABX464. Primary end              points – clinical remission at week 8 and 44. A Randomized, Double-blind, Placebo-controlled, Multicentre Phase III Study to Evaluate the                    Efficacy and Safety of ABX464 Once Daily for Induction Treatment in Subjects With Moderately to Severely Active Ulcerative Colitis. Recruitment        phase in Midlands Regional Hospital, Mullingar

 

  • Co-principal investigator in International Inflammatory Bowel Disease Study in UK and Ireland 2023– Using Jak Kinus Inhibitor, Filgotinib. A                  prospective, non-interventional, multi-country cohort study of the effectiveness and safety of Filgotinib in adult patients with moderately to                  severely active ulcerative colitis. Research question and Objectives – To describe the effectiveness, treatment patterns, quality of life and safety        of patients with moderately or severely active Ulcerative Colitis treated with Filgotinib in a real world setting. Recruitment phase in Midlands                Regional Hospital, Mullingar